AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29540864 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release guanfacine (GEXR)
Number of subjects: 62
Study 29540864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 26778524 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 60 mg (AT 60)
Number of subjects: 46
Study 26778524 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg (AT 20)
Number of subjects: 46
Study 26778524 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AT 60 mg and AT 20 mg)
Number of subjects: 46
Study 24643313 — intervention group
Group type: EXPERIMENTAL
Intervention: Family intervention delivered at individual, family, and community levels.
Number of subjects: 79
Study 23158914 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum total bilirubin (TBil) levels stratified into three groups: lower-level group (TBil ≤ 12.8 mmol/L), moderate-level group (TBil > 12.8 ∼ 18.2 mmol/L), higher-level group (TBil > 18.2 mmol/L)
Number of subjects: 140
Study 23158914 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum total bilirubin (TBil) levels
Number of subjects: 140
Study 23158914 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse pressure measurements
Number of subjects: 140
Study 19657349 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5 mg
Number of subjects: 450
Study 19657349 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg
Number of subjects: 450
Study 19657349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 18594091 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined popliteal and ankle block
Number of subjects: 63
Study 18594091 — intervention group
Group type: COMPARATOR
Intervention: Ankle block alone
Number of subjects: 63
Study 16205916 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg t.i.d.)
Number of subjects: 24
Study 16205916 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam (1 mg t.i.d.)
Number of subjects: 24
Study 16205916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12956257 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% once daily
Number of subjects: 1381
Study 12956257 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% twice daily
Number of subjects: 1381
Study 12956257 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005% once daily
Number of subjects: 1381
Study 10629018 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole cyclodextrin solution
Number of subjects: 40
Study 10629018 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole capsules
Number of subjects: 40
Study 8656304 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day fetal monitoring workshop and a review session 6 months later
Number of subjects: 109
Study 8656304 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 109
Study 1347039 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 20
Study 1347039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6395273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefonicid (1.0 g every 24 hr)
Number of subjects: 147
Study 6395273 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole (1.0 g iv every 6 hr)
Number of subjects: 147
Study 31034102 — intervention group
Group type: EXPERIMENTAL
Intervention: High expectations of improvement
Number of subjects: 593
Study 31034102 — intervention group
Group type: EXPERIMENTAL
Intervention: High expectations of improvement (controlling for potential confounders)
Number of subjects: 593
Study 31034102 — intervention group
Group type: COMPARATOR
Intervention: Baseline pain intensity, psychological profile, and self-rated health
Number of subjects: 593
Study 30128710 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin (n=284)
Number of subjects: 570
Study 30128710 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (n=286)
Number of subjects: 570
Study 26615509 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of meloxicam
Number of subjects: 36
Study 26615509 — intervention group
Group type: COMPARATOR
Intervention: 100 mg of diclofenac
Number of subjects: 36
Study 24216088 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa with benserazide
Number of subjects: 33
Study 22348456 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-extractive compound
Number of subjects: 0
Study 20662070 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5672 (20, 50, 100, or 150 mg orally, once daily)
Number of subjects: 371
Study 20662070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study 20662070 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (50 mg subcutaneously, once weekly)
Number of subjects: 371
Study 17931467 — intervention group
Group type: EXPERIMENTAL
Intervention: Unitary estimates of personal risk
Number of subjects: 0
Study 17931467 — intervention group
Group type: EXPERIMENTAL
Intervention: Bounded estimates
Number of subjects: 0
Study 17931467 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial unitary estimates
Number of subjects: 0
Study 17931467 — intervention group
Group type: COMPARATOR
Intervention: Estimates regarding the average student
Number of subjects: 0
Study 15770222 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose (OFS) 16 g/day for 8 weeks
Number of subjects: 7
Study 15770222 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrine (placebo)
Number of subjects: 7
Study 12075945 — intervention group
Group type: EXPERIMENTAL
Intervention: EBP Pak
Number of subjects: 327
Study 12075945 — intervention group
Group type: COMPARATOR
Intervention: VC Pak
Number of subjects: 327
Study 12075945 — intervention group
Group type: EXPERIMENTAL
Intervention: EBP Jar
Number of subjects: 327
Study 12075945 — intervention group
Group type: COMPARATOR
Intervention: VC Jar
Number of subjects: 327
Study 10395619 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose (Raftilose P95) 2 g three times daily for 4 weeks
Number of subjects: 21
Study 10395619 — intervention group
Group type: COMPARATOR
Intervention: Sucrose 1 g three times daily for 4 weeks (Control)
Number of subjects: 21
Study 7671182 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (calcium blocker)
Number of subjects: 0
Study 7671182 — intervention group
Group type: COMPARATOR
Intervention: No calcium blocker (control)
Number of subjects: 0
Study 2019378 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of single-agent cefotaxime, 2 g IV every 8 hours
Number of subjects: 100
Study 2019378 — intervention group
Group type: COMPARATOR
Intervention: 10 days of single-agent cefotaxime, 2 g IV every 8 hours
Number of subjects: 100
Study 7082501 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine infusion
Number of subjects: 6
Study 7082501 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside infusion
Number of subjects: 6
Study 7082501 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine infusion with cimetidine
Number of subjects: 6
Study 30482602 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization exercises plus neuromuscular electrical stimulation (n=15)
Number of subjects: 30
Study 30482602 — intervention group
Group type: COMPARATOR
Intervention: Stabilization exercises only (n=15)
Number of subjects: 30
Study 30106876 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine treatment with a 1-kg gain in body weight
Number of subjects: 47
Study 30106876 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine treatment with a 1-point increase in percentage of body fat
Number of subjects: 47
Study 26246430 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7009
Number of subjects: 92
Study 26246430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 23343614 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 0.03 mg/kg/d once daily before bed (group 2)
Number of subjects: 45
Study 23343614 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 20 mg/kg/d divided into 2 doses for pain control (group 1)
Number of subjects: 45
Study 21832031 — intervention group
Group type: EXPERIMENTAL
Intervention: Random schedule of grip force pattern training
Number of subjects: 0
Study 21832031 — intervention group
Group type: COMPARATOR
Intervention: Blocked schedule of grip force pattern training
Number of subjects: 0
Study 21832031 — intervention group
Group type: COMPARATOR
Intervention: Blocked schedule of grip force pattern training with poor visuospatial working memory
Number of subjects: 0
Study 21832031 — intervention group
Group type: EXPERIMENTAL
Intervention: Random schedule of grip force pattern training in individuals poststroke
Number of subjects: 0
Study 21832031 — intervention group
Group type: COMPARATOR
Intervention: Blocked schedule of grip force pattern training in individuals poststroke
Number of subjects: 0
Study 18313350 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil (EPO)
Number of subjects: 76
Study 18313350 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 76
Study 16492072 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide slow-release +/- Perindopril
Number of subjects: 0
Study 16492072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12707576 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 0
Study 10990013 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard setting according to the manufacturer's software
Number of subjects: 20
Study 10990013 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced gain and maximum output
Number of subjects: 20
Study 10990013 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 20
Study 10990013 — intervention group
Group type: COMPARATOR
Intervention: Both settings (standard and reduced)
Number of subjects: 20
Study 9166205 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial Laser Ablation (ELA)
Number of subjects: 372
Study 9166205 — intervention group
Group type: COMPARATOR
Intervention: Transcervical Resection of the Endometrium (TCRE)
Number of subjects: 372
Study 1603535 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival 5-fluorouracil (5-FU) injections, 4 to 6 injections over 10 days postoperatively.
Number of subjects: 41
Study 1603535 — intervention group
Group type: COMPARATOR
Intervention: No treatment with 5-fluorouracil (5-FU).
Number of subjects: 41
Study 3954937 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 2
Study 3954937 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg
Number of subjects: 2
Study 3954937 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 30 mg
Number of subjects: 2
Study 3954937 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 2
Study 29793446 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol administration
Number of subjects: 25
Study 29793446 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study 27546095 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD
Number of subjects: 24
Study 27546095 — intervention group
Group type: COMPARATOR
Intervention: Bio-Oss Collagen
Number of subjects: 24
Study 24237113 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Symptom Inventory (BSI) administered at 30, 90, and 180 days postinjury
Number of subjects: 872
Study 24237113 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender and race/ethnicity as factors in improvement rates
Number of subjects: 872
Study 24237113 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of clinically significant GSI elevations
Number of subjects: 872
Study 23009189 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modal exercise program (twice weekly, 60 minute classes for 16 weeks)
Number of subjects: 0
Study 23009189 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control group
Number of subjects: 0
Study 20102345 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholics Anonymous (AA) attendance
Number of subjects: 1706
Study 18319361 — intervention group
Group type: EXPERIMENTAL
Intervention: second-generation electrically heated cigarette smoking system (EHCSS)
Number of subjects: 97
Study 18319361 — intervention group
Group type: COMPARATOR
Intervention: conventional cigarettes
Number of subjects: 97
Study 18986412 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide administration
Number of subjects: 25
Study 15121562 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-based food supplement (n = 9) for 5 consecutive evenings
Number of subjects: 28
Study 15121562 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet (n = 19) for 5 consecutive evenings
Number of subjects: 28
Study 11509866 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. GH 0.1 IU/kg/day
Number of subjects: 8
Study 11509866 — intervention group
Group type: EXPERIMENTAL
Intervention: co-administration of GH and prednisolone
Number of subjects: 8
Study 11509866 — intervention group
Group type: COMPARATOR
Intervention: oral prednisolone 50 mg/day
Number of subjects: 8
Study 9380239 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-E-modified cellulose (CL-E) dialysis membranes
Number of subjects: 0
Study 9380239 — intervention group
Group type: COMPARATOR
Intervention: Conventional dialysis membranes
Number of subjects: 0
Study 8423488 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 192
Study 8423488 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk elevation with knee flexion position
Number of subjects: 192
Study 8423488 — intervention group
Group type: COMPARATOR
Intervention: Trunk elevation
Number of subjects: 192
Study 8423488 — intervention group
Group type: COMPARATOR
Intervention: Knee flexion
Number of subjects: 192
Study 2824861 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant medroxyprogesterone acetate (500 mg, 3 times a week for 1 year)
Number of subjects: 136
Study 2824861 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 136
Study 31541424 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacrosse non-slip elements (NSE)
Number of subjects: 79
Study 31541424 — intervention group
Group type: COMPARATOR
Intervention: Cutting balloons
Number of subjects: 79
Study 30138013 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 319
Study 30138013 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 319
Study 30138013 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (SRT)
Number of subjects: 319
Study 30138013 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT or COMB treatment
Number of subjects: 319
Study 30138013 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment remission
Number of subjects: 319
Study 30138013 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment responders and remitters
Number of subjects: 319
Study 26349936 — intervention group
Group type: EXPERIMENTAL
Intervention: High NaCl diet (32 g/d) supplemented with 90 mmol KHCO3/day for 10 days
Number of subjects: 8
Study 26349936 — intervention group
Group type: EXPERIMENTAL
Intervention: High NaCl diet (31 g/day)
Number of subjects: 8
Study 26349936 — intervention group
Group type: COMPARATOR
Intervention: Low NaCl diet (3 g/day) with acidified diet
Number of subjects: 8
Study 25702372 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Performance Coaching for stroke survivors (OPC‐Stroke), 10 sessions
Number of subjects: 0
Study 25702372 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 22782948 — intervention group
Group type: EXPERIMENTAL
Intervention: pegIFN-α2a/ribavirin therapy
Number of subjects: 0
Study 22782948 — intervention group
Group type: EXPERIMENTAL
Intervention: IL28B genotype
Number of subjects: 0
Study 20966595 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex plaque detected in patients assessed by 3DTEE
Number of subjects: 350
Study 20966595 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of complex plaque
Number of subjects: 350
Study 17924894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (up to 1 microg x kg(‐1))
Number of subjects: 60
Study 17924894 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (up to 5 mg)
Number of subjects: 60
Study 15717206 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 40
Study 15717206 — intervention group
Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation (sIMV)
Number of subjects: 40
Study 12419095 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 0.3%
Number of subjects: 48
Study 12419095 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim sulfate 0.1%/polymyxin B
Number of subjects: 48
Study 9450712 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine, 20 to 30 mg/d
Number of subjects: 81
Study 9450712 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline, targeted to a therapeutic plasma level of 190 to 570 nmol/L (50‐150 ng/mL)
Number of subjects: 81
Study 9450712 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 81
Study 9450712 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 81
Study 7649899 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol responses to exercise measured relative to circadian baselines
Number of subjects: 8
Study 7649899 — intervention group
Group type: COMPARATOR
Intervention: Cortisol responses to exercise measured relative to preexercise concentrations
Number of subjects: 8
Study 7649899 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol responses calculated relative to circadian baselines
Number of subjects: 8
Study 2628631 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-relevant content
Number of subjects: 0
Study 2628631 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood works
Number of subjects: 0
Study 2628631 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive thinking
Number of subjects: 0
Study 2628631 — intervention group
Group type: COMPARATOR
Intervention: Normal thinking (control)
Number of subjects: 0
Study 1181365 — intervention group
Group type: EXPERIMENTAL
Intervention: Group discussion program
Number of subjects: 70
Study 1181365 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual briefing program
Number of subjects: 70
Study 1181365 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 31628978 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ASA colon delivery system
Number of subjects: 0
Study 28673808 — intervention group
Group type: EXPERIMENTAL
Intervention: LARGE portion size (200% of SMALL, 2166 kcal)
Number of subjects: 20
Study 28673808 — intervention group
Group type: COMPARATOR
Intervention: SMALL portion size (1083 kcal)
Number of subjects: 20
Study 28673808 — intervention group
Group type: COMPARATOR
Intervention: NO TV
Number of subjects: 20
Study 28673808 — intervention group
Group type: EXPERIMENTAL
Intervention: TV
Number of subjects: 20
Study 25713485 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin plus metronidazole in combination with scaling and root planning (SRP)
Number of subjects: 28
Study 25713485 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planning (SRP) alone (control)
Number of subjects: 28
Study 23410871 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg before emergency PCI, followed by atorvastatin 40 mg for 4 weeks and atorvastatin 20 mg for 20 weeks (Group A)
Number of subjects: 102
Study 23410871 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg for 4 weeks and atorvastatin 20 mg for 20 weeks without pre-PCI loading dose (Group B)
Number of subjects: 102
Study 23410871 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg for 24 weeks only post-PCI (Group C)
Number of subjects: 102
Study 21639907 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab alone (5 mg/kg at weeks 0, 2, 6, 12, and 18)
Number of subjects: 26
Study 21639907 — intervention group
Group type: COMPARATOR
Intervention: Infliximab combined with Methotrexate (10 mg/week)
Number of subjects: 26
Study 19938941 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief iterative consultation
Number of subjects: 346
Study 19938941 — intervention group
Group type: COMPARATOR
Intervention: Control brochure
Number of subjects: 346
Study 17584550 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 300
Study 17584550 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 300
Study 15509358 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively framed strong messages advocating exercise from a credible source
Number of subjects: 450
Study 15509358 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively framed strong messages advocating exercise from a non-credible source
Number of subjects: 450
Study 15509358 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively framed strong messages advocating exercise from a credible source
Number of subjects: 450
Study 15509358 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively framed strong messages advocating exercise from a non-credible source
Number of subjects: 450
Study 15509358 — intervention group
Group type: COMPARATOR
Intervention: No-source control condition
Number of subjects: 450
Study 16422973 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 0
Study 16422973 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg
Number of subjects: 0
Study 16422973 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 5 mg
Number of subjects: 0
Study 16422973 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil (all doses)
Number of subjects: 0
Study 16422973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11762729 — intervention group
Group type: COMPARATOR
Intervention: No glove
Number of subjects: 41
Study 11762729 — intervention group
Group type: EXPERIMENTAL
Intervention: Leather glove
Number of subjects: 41
Study 11762729 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrile glove
Number of subjects: 41
Study 11762729 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinyl glove
Number of subjects: 41